Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma

Molecular Cell

Volumn 59, Issue 1, 2015, Pages 75-88

  Vardabasso, Chiara ^a   Gaspar Maia, Alexandre ^a   Hasson, Dan ^a   Pünzeler, Sebastian ^b   Valle Garcia, David ^a,c   Straub, Tobias ^b   Keilhauer, Eva C ^d   Strub, Thomas ^a   Dong, Joanna ^a   Panda, Taniya ^a   Chung, Chi Yeh ^a   Yao, Jonathan L ^a   Singh, Rajendra ^a   Segura, Miguel F ^e,g   Fontanals Cirera, Barbara ^e   Verma, Amit ^f   Mann, Matthias ^d   Hernando, Eva ^e   Hake, Sandra B ^b   Bernstein, Emily ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRD2 PROTEIN; HISTONE H2AZ; HISTONE H2AZ2; PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; BRD2 PROTEIN, HUMAN; E2F1 PROTEIN, HUMAN; HISTONE; HISTONE H2A.F-Z; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; BIOSYNTHESIS; CYTOLOGY; DRUG RESISTANCE; GENETICS; HELA CELL LINE; MELANOCYTE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; RNA INTERFERENCE; S PHASE CELL CYCLE CHECKPOINT; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; HELA CELLS; HISTONES; HUMANS; MELANOCYTES; MELANOMA; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; S PHASE CELL CYCLE CHECKPOINTS; SEQUENCE ANALYSIS, RNA; TRANSCRIPTIONAL ACTIVATION;

EID: 84937164820     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.05.009     Document Type: Article

References (45)

1. Alla V., Engelmann D., Niemetz A., Pahnke J., Schmidt A., Kunz M., Emmrich S., Steder M., Koczan D., Pützer B.M. E2F1 in melanoma progression and metastasis. J.Natl. Cancer Inst. 2010, 102:127-133.
2. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., Wei G., Chepelev I., Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
3. Belkina A.C., Denis G.V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 2012, 12:465-477.
4. Billon P., Côté J. Precise deposition of histone H2A.Z in chromatin for genome expression and maintenance. Biochim. Biophys. Acta 2013, 1819:290-302.
5. Bogunovic D., O'Neill D.W., Belitskaya-Levy I., Vacic V., Yu Y.L., Adams S., Darvishian F., Berman R., Shapiro R., Pavlick A.C., et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. USA 2009, 106:20429-20434.
6. Bönisch C., Hake S.B. Histone H2A variants in nucleosomes and chromatin: more or less stable?. Nucleic Acids Res. 2012, 40:10719-10741.
7. Ceol C.J., Houvras Y., Jane-Valbuena J., Bilodeau S., Orlando D.A., Battisti V., Fritsch L., Lin W.M., Hollmann T.J., Ferré F., et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011, 471:513-517.
8. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N.Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
9. Coleman-Derr D., Zilberman D. Deposition of histone variant H2A.Z within gene bodies regulates responsive genes. PLoS Genet. 2012, 8:e1002988.
10. Dawson M.A., Kouzarides T., Huntly B.J. Targeting epigenetic readers in cancer. N.Engl. J. Med. 2012, 367:647-657.
11. Denis G.V., Vaziri C., Guo N., Faller D.V. RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ. 2000, 11:417-424.
12. Denis G.V., McComb M.E., Faller D.V., Sinha A., Romesser P.B., Costello C.E. Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J.Proteome Res. 2006, 5:502-511.
13. Dhillon N., Oki M., Szyjka S.J., Aparicio O.M., Kamakaka R.T. H2A.Z functions to regulate progression through the cell cycle. Mol. Cell. Biol. 2006, 26:489-501.
14. Draker R., Ng M.K., Sarcinella E., Ignatchenko V., Kislinger T., Cheung P. A combination of H2A.Z and H4 acetylation recruits Brd2 to chromatin during transcriptional activation. PLoS Genet. 2012, 8:e1003047.
15. Dryhurst D., Ishibashi T., Rose K.L., Eirín-López J.M., McDonald D., Silva-Moreno B., Veldhoen N., Helbing C.C., Hendzel M.J., Shabanowitz J., et al. Characterization of the histone H2A.Z-1 and H2A.Z-2 isoforms in vertebrates. BMC Biol. 2009, 7:86.
16. Duarte L.F., Young A.R.J., Wang Z., Wu H.-A., Panda T., Kou Y., Kapoor A., Hasson D., Mills N.R., Ma'ayan A., et al. Histone H3.3 and its proteolytically processed form drive a cellular senescence programme. Nat. Commun. 2014, 5:5210.
17. Eberl H.C., Spruijt C.G., Kelstrup C.D., Vermeulen M., Mann M. A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics. Mol. Cell 2013, 49:368-378.
18. Faast R., Thonglairoam V., Schulz T.C., Beall J., Wells J.R., Taylor H., Matthaei K., Rathjen P.D., Tremethick D.J., Lyons I. Histone variant H2A.Z is required for early mammalian development. Curr. Biol. 2001, 11:1183-1187.
19. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
20. Greenwald R.J., Tumang J.R., Sinha A., Currier N., Cardiff R.D., Rothstein T.L., Faller D.V., Denis G.V. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 2004, 103:1475-1484.
21. Hasson D., Panchenko T., Salimian K.J., Salman M.U., Sekulic N., Alonso A., Warburton P.E., Black B.E. The octamer is the major form of CENP-A nucleosomes at human centromeres. Nat. Struct. Mol. Biol. 2013, 20:687-695.
22. Horikoshi N., Sato K., Shimada K., Arimura Y., Osakabe A., Tachiwana H., Hayashi-Takanaka Y., Iwasaki W., Kagawa W., Harata M., et al. Structural polymorphism in the L1 loop regions of human H2A.Z.1 and H2A.Z.2. Acta Crystallogr. D Biol. Crystallogr. 2013, 69:2431-2439.
23. Hu G., Cui K., Northrup D., Liu C., Wang C., Tang Q., Ge K., Levens D., Crane-Robinson C., Zhao K. H2A.Z facilitates access of active and repressive complexes to chromatin in embryonic stem cell self-renewal and differentiation. Cell Stem Cell 2013, 12:180-192.
24. Kapoor A., Goldberg M.S., Cumberland L.K., Ratnakumar K., Segura M.F., Emanuel P.O., Menendez S., Vardabasso C., Leroy G., Vidal C.I., et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 2010, 468:1105-1109.
25. Kaufman H.L., Kirkwood J.M., Hodi F.S., Agarwala S., Amatruda T., Bines S.D., Clark J.I., Curti B., Ernstoff M.S., Gajewski T., et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat. Rev. Clin. Oncol. 2013, 10:588-598.
26. Kou Y., Chen E.Y., Clark N.R., Tan C.M., Ma'ayan A. ChEA2: gene-set libraries from ChIP-X experiments to decode the transcription regulome. Multidisciplinary research and practice for information systems. CD-ARES 2013. Lect. Notes Comput. Sci. 2013, 8127:416-430.
27. Latorre I., Chesney M.A., Garrigues J.M., Stempor P., Appert A., Francesconi M., Strome S., Ahringer J. The DREAM complex promotes gene body H2A.Z for target repression. Genes Dev. 2015, 29:495-500.
28. LeRoy G., Rickards B., Flint S.J. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol. Cell 2008, 30:51-60.
29. LeRoy G., Chepelev I., DiMaggio P.A., Blanco M.A., Zee B.M., Zhao K., Garcia B.A. Proteogenomic characterization and mapping of nucleosomes decoded by Brd and HP1 proteins. Genome Biol. 2012, 13:R68.
30. Lito P., Rosen N., Solit D.B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 2013, 19:1401-1409.
31. Ma Y., Kurtyka C.A., Boyapalle S., Sung S.S., Lawrence H., Guida W., Cress W.D. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res. 2008, 68:6292-6299.
32. Matsuda R., Hori T., Kitamura H., Takeuchi K., Fukagawa T., Harata M. Identification and characterization of the two isoforms of the vertebrate H2A.Z histone variant. Nucleic Acids Res. 2010, 38:4263-4273.
33. Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M., Stoll I., Roy L., Reilly P.T., Mak T.W., et al. ANP32E is a histone chaperone that removes H2A.Z from chromatin. Nature 2014, 505:648-653.
34. Riker A.I., Enkemann S.A., Fodstad O., Liu S., Ren S., Morris C., Xi Y., Howell P., Metge B., Samant R.S., et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med. Genomics 2008, 1:13.
35. Sadeghi L., Bonilla C., Strålfors A., Ekwall K., Svensson J.P. Podbat: a novel genomic tool reveals Swr1-independent H2A.Z incorporation at gene coding sequences through epigenetic meta-analysis. PLoS Comput. Biol. 2011, 7:e1002163.
36. Sansoni V., Casas-Delucchi C.S., Rajan M., Schmidt A., Bonisch C., Thomae A.W., Staege M.S., Hake S.B., Cardoso M.C., Imhof A. The histone variant H2A.Bbd is enriched at sites of DNA synthesis. Nucleic Acids Res. 2014, 42:6405-6420.
37. Segura M.F., Fontanals-Cirera B., Gaziel-Sovran A., Guijarro M.V., Hanniford D., Zhang G., González-Gomez P., Morante M., Jubierre L., Zhang W., et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013, 73:6264-6276.
38. Sinha A., Faller D.V., Denis G.V. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem. J. 2005, 387:257-269.
39. Svotelis A., Gévry N., Gaudreau L. Regulation of gene expression and cellular proliferation by histone H2A.Z. Biochem. Cell Biol. 2009, 87:179-188.
40. Talantov D., Mazumder A., Yu J.X., Briggs T., Jiang Y., Backus J., Atkins D., Wang Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 2005, 11:7234-7242.
41. Vardabasso C., Hasson D., Ratnakumar K., Chung C.Y., Duarte L.F., Bernstein E. Histone variants: emerging players in cancer biology. Cell. Mol. Life Sci. 2013, 71:379-404.
42. Wiedemann S.M., Mildner S.N., Bönisch C., Israel L., Maiser A., Matheisl S., Straub T., Merkl R., Leonhardt H., Kremmer E., et al. Identification and characterization of two novel primate-specific histone H3 variants, H3.X and H3.Y. J.Cell Biol. 2010, 190:777-791.
43. Xu L., Shen S.S., Hoshida Y., Subramanian A., Ross K., Brunet J.P., Wagner S.N., Ramaswamy S., Mesirov J.P., Hynes R.O. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol. Cancer Res. 2008, 6:760-769.
44. Zilberman D., Coleman-Derr D., Ballinger T., Henikoff S. Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 2008, 456:125-129.
45. Zingg D., Debbache J., Schaefer S.M., Tuncer E., Frommel S.C., Cheng P., Arenas-Ramirez N., Haeusel J., Zhang Y., Bonalli M., et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun. 2015, 6:6051.